IRVINE, Calif., Nov. 20, 2025 -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01 (BAFFR-CAR T) have been accepted for oral presentations at the 2025 American Society of Hematology (ASH) Annual Meeting.
The abstracts showcase the emerging safety and efficacy profile of PMB-CT01 in heavily pretreated r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) and r/r B-cell Non-Hodgkin Lymphoma (B-NHL), including patients who failed prior CD19-directed therapy or presented with CD19-negative disease. Interim results from the Phase 1 dose-escalation studies (NCT04690595, NCT05370430) support BAFF-R as a differentiated target designed to overcome CD19 antigen escape while maintaining durable activity and low toxicity.
r/r B-NHL
Safety:
PMB-CT01 demonstrated an exceptionally favorable tolerability profile. No Grade ˃1 Cytokine Release Syndrome (CRS) and no Grade ˃1 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Efficacy:
All the first 7 patients achieved a Complete Response (CR) at 1–3 months post-infusion, including those previously treated with CD19 CAR T therapy and those with CD19-negative disease.
Durability:
Remissions have remained ongoing for up to 32+ months (median 17 months) at data cutoff.
r/r B-ALL
Efficacy:
Four of six enrolled patients achieved an undetectable Minimal Residual Disease (MRD-) Complete Remission (CR)
High-Risk Population:
Three of the four responders were CD19-negative at enrollment. All three successfully transitioned to allogeneic hematopoietic cell transplant (HCT) with curative intent.
Safety:
No Dose-Limiting Toxicities (DLTs) were observed. Only one patient experienced Grade 2 CRS, with no Grade 3 CRS reported.
"The consistent and durable activity seen across both B-ALL and B-NHL, particularly in patients who have exhausted CD19 CAR T options or present with CD19-negative disease, strongly supports BAFF-R as a highly effective and safe alternative target," said Hazel Cheng, Ph.D., COO of PeproMene Bio. "These data highlight PMB-CT01's potential to address critical unmet needs in high-risk relapsed disease."
ASH 2025 Oral Presentations
Abstract Title:
BAFFR-CAR T cells demonstrate durable responses and manageable toxicities in r/r B-cell lymphomas…
Abstract: abs25-7079
Date/Time: December 6, 2:45 PM
Presenter: Elizabeth Budde, M.D., Ph.D.
Abstract Title:
BAFFR-CAR T cells show promising safety and anti-leukemia efficacy in r/r B-cell ALL patients…
Abstract:
abs25-2035
Date/Time:
December 8, 11:00
AM
Presenter:
Ibrahim
Aldoss, M.D.
(Dates/times are placeholders.)
About PMB-CT01
PMB-CT01 is a first-in-class BAFF-R–targeted autologous CAR T cell therapy. BAFF-R is expressed almost exclusively on B cells and is essential for B-cell survival, reducing the likelihood of antigen-loss escape. PMB-CT01 is being evaluated in Phase 1 trials for r/r B-NHL and r/r B-ALL.
Forward-Looking Statements
This press release contains forward-looking statements subject to risks and uncertainties, including risks related to clinical development, regulatory outcomes, therapeutic potential, and commercialization. PeproMene Bio undertakes no obligation to update forward-looking statements except as required by law.
Media/Investor
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
